Global Resistant Hypertension Treatment Market: Overview Hypertension is one of the common untreated diseases and poses major risk for heart failure, renal failure, cerebrovascular disease, cardiovascular disease, and coronary heart disease. About less than half of hypertensive patients in the U.S. are using economical generic antihypertensive drugs (AHDs). About 5%-10% (maximum to 20%-30%) of hypertensive patients with incompetently controlled hypertension have resistant hypertension. Read Report Overview - https://www.transparencymarketresearch.com/resistant-hypertensiontreatment-market.html Resistant hypertension is a condition when the blood pressure remains higher than the normal range despite optimum dosage of three antihypertensive drugs, including a diuretics. Resistant hypertension includes patients whose blood pressure controlled on ≥ 4 antihypertensive drugs, but excludes those with uncontrolled blood pressure on <3 antihypertensive drugs or suboptimal antihypertensive drugs regimen. According to the latest research studies, prevalence rate of resistant hypertension is estimated to increase in the future. Resistant hypertension is found in patients with chronic kidney disease (CKD), lef ventricular hypertrophy (LVH), diabetes, higher systolic BP, obesity, and also among elderly patients. Resistant hypertensive patients are at higher risk of serious cardiovascular outcomes, hospitalization, and heart stroke, in particular. Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php? flag=B&rep_id=41111 Global Resistant Hypertension Treatment Market: Drivers and Restraints Resistant hypertension is different from uncontrolled hypertension. For a precise identification of prevalence of resistant hypertension, a compulsory titration study of a large and diverse hypertensive group is required. Resistant hypertension denotes a risky phenotype. Genetic factors play a more crucial role in resistant hypertension as compared to general hypertension. Although for resistant hypertensive patients, genetic valuations are limited. In one of the limited genetic assessments of patients in Finland, investigators screened 347 patients with resistant hypertension who had mutation on the γ and β subunits of the epithelial sodium channel. Mutation on the γ and β subunits can cause Liddle’s syndrome. Liddle’s syndrome is a rare form of hypertension (monogenic). According to data collected by the National Health and Nutrition Examination Survey (NHANES) from its study of samples of non-institutionalized, adult, civilian population, the prevalence rate of resistant hypertension was estimated around 8.9?±?0.6% among the population of the U.S. during 2003 to 2008. The study suggests that resistant hypertension and hypertension have become wide-spread due to increase of obesity among the general population and growth in geriatric population. Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php? flag=CR&rep_id=41111 Resistant hypertension is more prevalent among the non-black Hispanic or African America, male, obese, and elderly population. The global resistant hypertension treatment market has been expanding over the
Resistant Hypertension Treatment Market Set to Record Exponential Growth by 2025
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.